What is Kanna used for?

Kanna (Mesembryanthemum tortuosum) carries a Grade C rating — limited evidence. Strongest recorded design is a narrative review, drawn from 3 recorded studies, none of which measured an outcome in people. Recorded activity centres on neurotransmitter modulation, stress response modulation and serotonergic, which describes mechanism rather than demonstrated benefit. Noted cautions include pregnancy/breastfeeding and bipolar/mania risk.

Herb Profile

Kanna

Mesembryanthemum tortuosum

Kanna (Mesembryanthemum tortuosum) carries a Grade C rating — limited evidence.

Last reviewed: June 6, 2026•3 sources citedReport a correctionProfile-wide ·C Limited

Use extra caution — CNS active and potentially serotonergic. Details

Evidence: Limited Evidence
Typical onset: Varies by prep
Safety rating: High caution
Best for: Mood Support, Anti Anxiety, Empathogen, Stress
Avoid / review if: Pregnancy/Breastfeeding, Bipolar/Mania Risk, Serotonin Syndrome Risk

The Hippie Scientist

At a glance

From this profile's structured data

Evidence: Grade C
Safety: CNS-active and potentially serotonergic.
Profile context: mood_support, anti_anxiety, empathogen

Next stepsWhere to go next — guides & comparisons

If you want help with anxiety or stress → Anxiety & stress guides
If you want to browse more herbs → All herbs

Safety

Safety & Cautions

CNS active and potentially serotonergic. Avoid casual stacking with antidepressants or empathogenic/stimulant products.

High caution

Caution level: High. Multiple caution categories apply, or the record uses avoid/contraindication language.

Interaction-AwareMedication or interaction context is explicitly noted.
Stimulant-Like ProfileStimulant-like or activating caution language is present.
Pregnancy/Breastfeeding CautionPregnancy or breastfeeding caution language is present.

Detailed safety fields

Pregnancy, breastfeeding, and contraindications

Pregnancy/Breastfeeding
Bipolar/Mania Risk
Serotonin Syndrome Risk
Active Psychiatric Medication Use Without Clinician Oversight.
Avoid Or Clinician Review With SSRIs
SNRIs
MAOIs
TCAs
Lithium
Tramadol

Safety classifications

Interaction-Aware: Medication or interaction context is explicitly noted.
Stimulant-Like Profile: Stimulant-like or activating caution language is present.
Pregnancy/Breastfeeding Caution: Pregnancy or breastfeeding caution language is present.

Full safety note

CNS active and potentially serotonergic. Avoid casual stacking with antidepressants or empathogenic/stimulant products.

Safety labels

Interaction-Aware
Stimulant-Like Profile
Pregnancy/Breastfeeding Caution

Evidence-based safety

Caution when combined

Severity and certainty are shown separately. A high-priority caution can still be theoretical: these pairings are screened from shared contraindication mechanisms and are not automatically documented clinical interactions. Provenance identifies the source fields that produced each flag; it does not upgrade the certainty of the pairwise claim.

High-Priority Caution

26 flagged pairings

Serotonergic activity

Representative pairings are shown below. Large mechanism groups are intentionally summarized to keep profiles focused and crawl-efficient.

Serotonergic activityCertainty: Theoretical

Data provenance recorded for 26 of 26 pairings in this mechanism group.

5-HTP — Theoretical interaction certainty
Caffeine — Theoretical interaction certainty
crocetin — Theoretical interaction certainty
crocin — Theoretical interaction certainty
Crocus Sativus — Theoretical interaction certainty
Damiana — Theoretical interaction certainty
DMT — Theoretical interaction certainty
Ginkgo — Theoretical interaction certainty
Panax Red Ginseng — Theoretical interaction certainty
Panax White Ginseng — Theoretical interaction certainty
Harmaline — Theoretical interaction certainty
Harmine — Theoretical interaction certainty

+14 more pairings share this mechanism. Use the Safety Checker to review a specific combination.

Evidence

Evidence Summary

Evidence lens

Read as directional context, not settled clinical proof.

LimitedLimited Evidence

Human clinical evidence: Not the primary signal

Mechanistic / preclinical: Mechanism mapped — Neurotransmitter Modulation · Stress Response Modulation

Research maturity: Theoretical / mechanistic research — Mechanistic or unresolved evidence is kept separate from established human outcomes.

Safety boundary: Safety note available — CNS active and potentially serotonergic.

This profile cites 3 human studies.

Study design details

Evidence Grade

Grade C: Limited Evidence

Evaluation of methodological rigor, population reach, and evidence alignment.

Design Match: Narrative review
Risk of Bias: High
Consistency: Not assessed

Strongest recorded design is a narrative review, drawn from 3 recorded studies, none of which measured an outcome in people.

How evidence grades work

Each grade reflects the strength and consistency of published human evidence — not marketing claims. Grades are based on study count, design quality, effect size, consistency, and recency.

Strong: Multiple RCTs, consistent direction, adequate effect size
Moderate: Some RCTs or consistent observational data in humans
Preliminary / Mixed: Animal or in-vitro only, or conflicting human data
Traditional / Theoretical: Traditional use only; no controlled human trials

Clinical Study Summaries (4)0 human evidence sources · 0 human trials · Participant totals not consistently reported · Consistency not yet classifiable

Filter by study class

Showing 4 of 4 studies.

What the evidence actually shows

This table contains 4 structured sources, including 0 human evidence sources; 0 are human trials. A reliable participant total cannot be calculated because sample size is not consistently structured in the cited sources. Source-to-conclusion relationships are not classified in this structured set, so consistency is not yet classifiable.

Profile-wide evidence grade: see the profile grade above · Confidence: not separately assigned

What would change our conclusion?

Larger, well-controlled human trials using comparable populations, doses, preparations, and clinically meaningful outcomes could materially strengthen or weaken this conclusion. Replication in a different population or a high-quality synthesis resolving current disagreement could also materially change confidence.

Study	Design	N	Dose	Duration	Population	Outcome	Result & magnitude	Source
A Chewable Cure "Kanna": Biological and Pharmaceutical Properties of Sceletium tortuosum Manganyi MC et al. · Molecules · 2021 Background	Narrative review Summarizes selected literature without the full prespecified search and selection methods of a systematic review.	—	—	—	—	—	—	PubMed →
Mesembrine alkaloids: Review of their occurrence, chemistry, and pharmacology Krstenansky JL et al. · J Ethnopharmacol · 2017 Background	Narrative review Summarizes selected literature without the full prespecified search and selection methods of a systematic review.	—	—	—	—	—	—	PubMed →
Mesembryanthemum tortuosum and Zembrin: mixed evidence review Background	Animal research Tests effects in non-human animals. Useful for hypotheses and safety signals, but results may not translate to people.	—	—	—	—	—	A 2025 critical review found mixed human evidence: small studies suggest possible anxiety/stress, cognitive, and mood signals, but outcomes are inconsistent and many studies use healthy volunteers rather than clinically relevant populations. Large, condition-specific trials are still needed.	DOI →
GC-MS, LC-MS(n), LC-high resolution-MS(n), and NMR studies on the metabolism and toxicological detection of mesembrine and mesembrenone, the main alkaloids of the legal high "Kanna" isolated from Sceletium tortuosum Meyer GM et al. · Anal Bioanal Chem · 2015 Background	Other / unclear The study design is not yet classified clearly enough to infer its place in the evidence hierarchy.	—	—	—	—	—	—	PubMed →

Dosing & Timing

No standardized dose: Preparation specific; use standardized product label for Fermented aerial material and require source backed dosage review before therapeutic claims.

How Kanna works

Simplified mechanism pathway based on preclinical and pharmacological evidence. Does not confirm clinical efficacy.

Mechanism Pathway — How Kanna Works

CompoundTarget / ReceptorMechanismEffect / Outcome

Mechanisms & biological pathways

Preclinical pathways. Proposed mechanisms from in vitro and animal research; these do not confirm clinical outcomes in humans.

Neurotransmitter Modulation
Stress Response Modulation

Active Compounds

Key constituents studied in Kanna, with full pharmacology and safety profiles.

Compare related active botanicals

Explore botanicals with similar chemistry, effects, or safety considerations in the Botanical Activity Atlas.

Compare & Sourcing

Compare side-by-side tradeoffs or verify active marker guidelines.

Sourcing options

Kanna product picks

Recommendation status

Product recommendations are not shown for this profile because the current site safety and monetization policy does not permit them.

Product form & quality guidelines

When sourcing Kanna, verify the label for:

Standardized extract: Confirm active content percentages on the supplement facts panel (e.g. standardized to specific marker compounds) rather than simple raw herb weights.
Third-party testing: Look for independent purity labels (USP, NSF, ConsumerLab, or Eurofins) to ensure the product is free from heavy metals, solvents, and contaminants.
Form bioavailability: Ensure the form matches evidence-supported configurations (e.g. standardized active extracts like bacosides, withanolides, or curcuminoids) for optimal onset and digestion tolerance.

Safety first · Harm reduction

This information is educational and not medical advice. Start low, avoid risky combinations, and consult a licensed clinician before making health decisions—especially if you use medications, have diagnosed conditions, or are pregnant/breastfeeding.

Learn how we evaluate confidence, safety, and intensity on the methodology page.

Editorial Review

Checked against primary sources, cited evidence, and contraindication language before publication. Evidence claims, safety language, and affiliate modules are reviewed independently. Not personal medical advice.

Editorial Standards →

Help improve this profile

Was this useful for your research?

These controls record only the page and the structured choice you make when analytics consent is enabled. Please don’t include personal medical information in research requests.

Was this evidence summary clear?

Did you find what you were researching?

Suggest an ingredient, comparison, or study →

Free safety checklist

Get the Kanna research notes

Evidence summaries, dosing context, and safety updates for this herb — straight to your inbox.

We use your email to send the checklist and occasional evidence-first supplement updates. Unsubscribe anytime. Privacy policy.

← Back to herbs library Safety checker →

Botanical profile context

How to interpret Kanna

Kanna herb profile with evidence context, key research topics, source notes, safety context, and references presented in an evidence-first format. Use this herb profile as a starting point for evidence review, not as a recommendation to start a new supplement. Botanical products can vary by plant part, extract ratio, standardization, dose, and contaminant testing, so two labels with the same common name may not behave the same way.

When reviewing Kanna, compare the traditional-use context against the human evidence, mechanism notes, and safety cautions. Pay special attention to pregnancy, breastfeeding, liver or kidney disease, blood-pressure effects, sedation, stimulation, anticoagulant use, antidepressants, and any prescription medication overlap.

For product decisions, prefer transparent labels, named extracts, clear serving sizes, and third-party quality testing. Avoid treating a long list of possible mechanisms as proof that an herb will solve a specific condition.